EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioMarin Pharmaceutical's Enterprise Value is €9,347 Mil.
BioMarin Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €652 Mil. Therefore, BioMarin Pharmaceutical's EV-to-FCF for today is 14.34.
The historical rank and industry rank for BioMarin Pharmaceutical's EV-to-FCF or its related term are showing as below:
HAM:BM8'
s EV-to-FCF Range Over the Past 10 Years
Min: -7283.59 Med: 11.22 Max: 886.53
Current: 14.02
During the past 13 years, the highest EV-to-FCF of BioMarin Pharmaceutical was 886.53. The lowest was -7283.59. And the median was 11.22.
HAM:BM8's EV-to-FCF is ranked better than 53.5% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs HAM:BM8: 14.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioMarin Pharmaceutical's PE Ratio (TTM) for today is calculated as:
BioMarin Pharmaceutical's share price for today is €52.24.
BioMarin Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.192.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioMarin Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's EV-to-FCF falls into.
BioMarin Pharmaceutical's current Enterprise Value is €9,347 Mil.
BioMarin Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €652 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (HAM:BM8) has a EV-to-FCF of 14.34 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioMarin Pharmaceutical and its competitors. This is 28% above median its historical median of 11.22. According to the industry distribution chart, BioMarin Pharmaceutical ranks #153 out of 329 companies in the Biotechnology industry, placing it in the top 46.5%.
Is BioMarin Pharmaceutical's EV-to-FCF too high?
BioMarin Pharmaceutical's current EV-to-FCF of 14.34 is 28% above median its 10-year median of 11.22. The Biotechnology industry median EV-to-FCF is 15.85. BioMarin Pharmaceutical's value of 14.34 is 9.5% below this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #153 out of 329 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's EV-to-FCF compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #153 out of 329 companies for EV-to-FCF. This puts BioMarin Pharmaceutical in the upper half of its industry. The industry median EV-to-FCF is 15.85. BioMarin Pharmaceutical's value of 14.34 is 9.5% below this benchmark. While the company's 10-year median is 11.22 vs. the industry median of 15.85, BioMarin Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current EV-to-FCF of 14.34 is 9.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current EV-to-FCF is 14.34, which is 28% above median its own 10-year median of 11.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current EV-to-FCF of 14.34. The stock's GF Value™ is €77.85, compared to a current price of €52.24 — trading 32.9% below its estimated fair value. The current EV-to-FCF is 14.34, which is 28% above median its 10-year median of 11.22 and 9.5% below the Biotechnology industry median of 15.85. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current EV-to-FCF is 14.34 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of €52.24 is trading 32.9% below its estimated GF Value™ of €77.85.
Key valuation signals for HAM:BM8:
EV-to-FCF: 14.34 (28% above median its 10-year median of 11.22)
GF Value™: €77.85 vs. price of €52.24 (32.9% below fair value)
Industry Position: 9.5% below the Biotechnology median (#153 of 329)
No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score
Get the complete analysis for HAM:BM8
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BM8 has been successfully added to your 
